Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Cerebrospinal Fluid Concentration of Daptomycin (Cubicin) in Pediatric Patients With Gram-positive Bacterial Meningitis, Concurrently Receiving Standard Antimicrobial Therapy

Next Previous
X
Search
Trial Profile

Evaluation of Cerebrospinal Fluid Concentration of Daptomycin (Cubicin) in Pediatric Patients With Gram-positive Bacterial Meningitis, Concurrently Receiving Standard Antimicrobial Therapy

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daptomycin (Primary) ; Ceftriaxone
  • Indications Bacterial meningitis; Gram-positive infections
  • Focus Pharmacokinetics

    • Most Recent Events

    • 09 Oct 2018 Status changed from recruiting to discontinued.
    • 10 Dec 2015 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018 as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top